Odyssey Group International Inc. (ODYY)
| Market Cap | 24.57M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 82.72M |
| EPS (ttm) | -0.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,574 |
| Open | 0.3022 |
| Previous Close | 0.3210 |
| Day's Range | 0.2901 - 0.3246 |
| 52-Week Range | 0.1050 - 2.0000 |
| Beta | 1.49 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About ODYY
Odyssey Group International, Inc. focuses on development, acquisition, and commercialization of medical products and health related technologies. It intends to offer medical devices. The company has development projects in three technologies, including CardioMap, a heart monitoring and screening device; Save A Life choking rescue device; and a neurosteroid drug compound intended to treat rare brain disorders. Odyssey Group International, Inc. was founded in 2014 and is based in Irvine, California.
Financial Performance
Financial StatementsNews
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
IRVINE, CA, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical ...
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
IRVINE, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a medical company focused on developing unique, life-saving medical products, ...
Odyssey Group International Approved to Start Human Trial to Treat Concussion
IRVINE, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today an...
Odyssey Group International Completes IND-enabling Studies, Submits Investigator's Brochure for Phase 1 Clinical Trial
IRVINE, CA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-s...
Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders
IRVINE, CA, July 26, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a t...
Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Conc...
IRVINE, CA, June 29, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life...
Odyssey Group International to Present at LD Micro Virtual Investor Conference
IRVINE, CA, June 08, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, lif...
Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treatin...
Irvine, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life...
Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug
Enters Agreement with Contract Research Organization for Phase 1 Trial Enters Agreement with Contract Research Organization for Phase 1 Trial
Odyssey Group International, Inc. Schedules Annual Meeting of Stockholders
IRVINE, CA, May 24, 2021 (GLOBE NEWSWIRE) -- – Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a t...
Odyssey Group International Welcomes Global Operations and Quality Leader Ricky Richardson to Board of Directors
IRVINE, CA, May 13, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"),a technology and asset acquisition company focused on developing unique, life-...
Odyssey Group International Announces Formation of Scientific Advisory Board
Irvine, CA, April 14, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, lif...
Odyssey Group International to Present at Virtual Investor Summit on March 24, 2021 at 2:30 PM ET
CEO Michael Redmond to Highlight the Company's Strategy in Developing and Acquiring Life-Saving Medical Products IRVINE, CA / ACCESSWIRE / March 22, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY)...
Odyssey Group International Announces Formation of Sports Advisory Board to Enhance Awareness of Traumatic Brain Inju...
Inaugural members of the Sports Advisory Board (SAB) include Kurt Warner, Brett Favre, Mark Rypien, David Ross and Steve “Mooch” Mariucci Inaugural members of the Sports Advisory Board (SAB) include Kur...
Odyssey Group International Announces Upcoming Television Appearance by Brett Favre and Dr. Jake VanLandingham on New...
IRVINE, CA / ACCESSWIRE / March 10, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-savi...
Odyssey Group International, Inc. Closes Acquisition of Novel Concussion Drug
Anticipates initiation of Phase 1 clinical trials of PRV-002 during the Second Quarter of 2021 IRVINE, CA / ACCESSWIRE / March 2, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) ("Odyssey"), a tec...
Odyssey Group International to Acquire Concussion Drug Asset from Prevacus, Inc.
All Stock Transaction Phase 1 Clinical Trial Site, Protocol and CRO Established IRVINE, CA / ACCESSWIRE / January 11, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), ...